Silver Book Fact

Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.

Black, Dennis M. Desmond E. Thompson, Douglas C. Bauer, Kris Ensrud, Thomas Musliner, Marc C. Hochberg, Michael C. Nevitt, Shailaja Suryawanshi, and Steven R. Cummings; for the FIT Research Group. Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The fracture intervention trial. J Clin Endocrinol Metabo. 2000; 85(11): 4118-24. http://jcem.endojournals.org/cgi/content/full/85/11/4118

Reference

Title
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The fracture intervention trial
Publication
J Clin Endocrinol Metabo
Publication Date
2000
Authors
Black, Dennis M. Desmond E. Thompson, Douglas C. Bauer, Kris Ensrud, Thomas Musliner, Marc C. Hochberg, Michael C. Nevitt, Shailaja Suryawanshi, and Steven R. Cummings; for the FIT Research Group
Volume & Issue
Volume 85, Issue 11
Pages
4118-24
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Clinical studies in nutrition and physical activity interventions have proven that fractures can be prevented, even in older individuals, and that they do not need to be a natural consequence…  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
  • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.